Economic Impact of Human Papillomavirus-Associated Head and Neck Cancers in the United States

Otolaryngologic Clinics of North America

Volumn 45, Issue 4, 2012, Pages 899-917

  Coughlan, Diarmuid ^a,b   Frick, Kevin D ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Cost; Economic evaluation; Economics; Head and neck cancer; Human papillomavirus; Oropharyngeal cancer

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; PACLITAXEL;

ABSENTEEISM; BUDGET; CANCER PATIENT; CANCER SCREENING; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; ECONOMIC ASPECT; HEAD AND NECK CANCER; HEALTH CARE COST; HUMAN; INCIDENCE; INTENSITY MODULATED RADIATION THERAPY; INTERNATIONAL CLASSIFICATION OF DISEASES; MANAGED CARE; MEDICAL LEAVE; MEDICARE; MORBIDITY; MORTALITY; MOUTH CANCER; NONHUMAN; OROPHARYNX CANCER; PATIENT CARE; PRODUCTIVITY; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RECURRENCE RISK; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; UNITED STATES; WART VIRUS;

CARCINOMA, SQUAMOUS CELL; COST OF ILLNESS; HEAD AND NECK NEOPLASMS; HEALTH CARE COSTS; HUMANS; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UNITED STATES;

EID: 84863868495     PISSN: 00306665     EISSN: 15578259     Source Type: Journal    
DOI: 10.1016/j.otc.2012.05.002     Document Type: Review

References (93)

1. Sturgis E.M., Cinciripini P.M. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers?. Cancer 2007, 110(7):1429-1435.
2. Näsman A., Attner P., Hammarstedt L., et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma?. Int J Cancer 2009, 125(2):362-366.
3. Marur S., D'Souza G., Westra W.H., et al. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010, 11(8):781-789.
4. Sturgis E.M., Ang K.K. The epidemic of HPV-associated oropharyngeal cancer is here: is it time to change our treatment paradigms?. J Natl Compr Canc Netw 2011, 9(6):665-673.
5. Chaturvedi A.K., Engels E.A., Pfeiffer R.M., et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011, 29(32):4294-4301.
6. D'Souza G., Agrawal Y., Halpern J., et al. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis 2009, 199(9):1263-1269.
7. Adelstein D.J., Rodriguez C.P. Human papillomavirus: changing paradigms in oropharyngeal cancer. Curr Oncol Rep 2010, 12(2):115-120.
8. Gillison M.L. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol 2004, 31(6):744-754.
9. Kreimer A.R. Oral sexual behaviors and the prevalence of oral human papillomavirus infection. J Infect Dis 2009, 199(9):1253-1254.
10. Landro L. Throat cancer linked to virus [Internet]. wsjcom. 2011. Available at: Accessed June 11, 2012. http://online.wsj.com/article/SB10001424052702303657404576355403363380510.html.
11. Frick K.D., Kymes S.M. The calculation and use of economic burden data. Br J Ophthalmol 2006, 90(3):255-257.
12. van Monsjou H.S., Balm A.J.M., van den Brekel M.M., et al. Oropharyngeal squamous cell carcinoma: a unique disease on the rise?. Oral Oncol 2010, 46(11):780-785.
13. Larg A., Moss J.R. Cost-of-illness studies: a guide to critical evaluation. Pharmacoeconomics 2011, 29(8):653-671.
14. Rosen A.B., Cutler D.M. Challenges in building disease-based national health accounts. Med Care 2009, 47(7 Suppl 1):S7-S13.
15. Clabaugh G., Ward M.M. Cost-of-illness studies in the United States: a systematic review of methodologies used for direct cost. Value Health 2008, 11(1):13-21.
16. Menzin J., Lines L.M., Manning L.N. The economics of squamous cell carcinoma of the head and neck. Curr Opin Otolaryngol Head Neck Surg 2007, 15(2):68-73.
17. Lee J.M., Turini M., Botteman M.F., et al. Economic burden of head and neck cancer. A literature review. Eur J Health Econ 2004, 5(1):70-80.
18. Selke B., Allenet B., Bercez C., et al. Economic assessments of head and neck cancers: a review. Bull Cancer 2001, 88(8):759-764.
19. Hu D., Goldie S. The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol 2008, 198(5):500. e1-7.
20. Ekwueme D.U., Chesson H.W., Zhang K.B., et al. Years of potential life lost and productivity costs because of cancer mortality and for specific cancer sites where human papillomavirus may be a risk factor for carcinogenesis-United States, 2003. Cancer 2008, 113(Suppl 10):2936-2945.
21. Lang K., Menzin J., Earle C.C., et al. The economic cost of squamous cell cancer of the head and neck: findings from linked SEER-Medicare data. Arch Otolaryngol Head Neck Surg 2004, 130(11):1269-1275.
22. Amonkar M.M., Chastek B., Samant N., et al. Economic burden of resected squamous cell carcinoma of the head and neck in a US managed-care population. J Med Econ 2011, 14(4):421-432.
23. Adelstein D.J., Ridge J.A., Gillison M.L., et al. Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck 2009, 31(11):1393-1422.
24. Le T.K., Winfree K.B., Yang H., et al. Health care resource utilization and economic burden of metastatic and recurrent locally-advanced head and neck cancer patients. Value Health 2011, 14(3):A172-A173.
25. Choi J., Joish V., Camacho F., et al. First year cost expenditures associated with head and neck cancer diagnosis in the U.S. managed care population. Value Health 2009, 12(3):A47-A48.
26. Epstein J.D., Knight T.K., Epstein J.B., et al. Cost of care for early- and late-stage oral and pharyngeal cancer in the California Medicaid population. Head Neck 2008, 30(2):178-186.
27. Wong S.J., Harari P.M., Garden A.S., et al. Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN): analysis of chemoradiation treatment approaches in the United States. Cancer 2011, 117(8):1679-1686.
28. NCCN clinical practice guidelines in oncology [Internet]. Available at: Accessed July 22, 2011. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
29. Ahmed A., Cascarini L., Sandison A., et al. Survey of the use of tests for human papilloma virus and epidermal growth factor receptor for squamous cell carcinoma of the head and neck in UK head and neck multidisciplinary teams. Br J Oral Maxillofac Surg 2011, 50(2):119-121. [Internet].
30. Ackerman S.J., Smith M.D., Ehreth J., et al. Therapeutic and diagnostic device outcomes research 2011, ISPOR, Lawrenceville (NJ).
31. Scott M.G. When do new biomarkers make economic sense?. Scand J Clin Lab Invest Suppl 2010, 242:90-95.
32. Sedaghat A.R., Zhang Z., Begum S., et al. Prognostic significance of human papillomavirus in oropharyngeal squamous cell carcinomas. Laryngoscope 2009, 119(8):1542-1549.
33. Fakhry C., Westra W.H., Li S., et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008, 100(4):261-269.
34. Weinberger P.M., Yu Z., Haffty B.G., et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006, 24(5):736-747.
35. Licitra L., Perrone F., Bossi P., et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006, 24(36):5630-5636.
36. Reimers N., Kasper H.U., Weissenborn S.J., et al. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer 2007, 120(8):1731-1738.
37. Tribius S., Ihloff A.S., Rieckmann T., et al. Impact of HPV status on treatment of squamous cell cancer of the oropharynx: what we know and what we need to know. Cancer Lett 2011, 304(2):71-79.
38. Ihloff A.S., Petersen C., Hoffmann M., et al. Human papilloma virus in locally advanced stage III/IV squamous cell cancer of the oropharynx and impact on choice of therapy. Oral Oncol 2010, 46(10):705-711.
39. Oliver R.J., Clarkson J.E., Conway D.I., et al. Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment. Cochrane Database Syst Rev 2007, 4. CD006205.
40. Furness S., Glenny A.M., Worthington H.V., et al. Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. Cochrane Database Syst Rev 2011, 4. CD006386.
41. Glenny A.M., Furness S., Worthington H.V., et al. Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy. Cochrane Database Syst Rev 2010, 12. CD006387.
42. Gourin C.G., Forastiere A.A., Sanguineti G., et al. Impact of surgeon and hospital volume on short-term outcomes and cost of oropharyngeal cancer surgical care. Laryngoscope 2011, 121(4):746-752.
43. Jones N.F., Jarrahy R., Song J.I., et al. Postoperative medical complications-not microsurgical complications-negatively influence the morbidity, mortality, and true costs after microsurgical reconstruction for head and neck cancer. Plast Reconstr Surg 2007, 119(7):2053-2060.
44. Garden A.S., Kies M.S., Weber R.S. To TORS or not to TORS: but is that the question?: comment on "transoral robotic surgery for advanced oropharyngeal carcinoma". Arch Otolaryngol Head Neck Surg 2010, 136(11):1085-1087.
45. Goon P.K., Stanley M.A., Ebmeyer J., et al. HPV & head and neck cancer: a descriptive update. Head Neck Oncol 2009, 1:36.
46. Sher D.J. Cost-effectiveness studies in radiation therapy. Expert Rev Pharmacoecon Outcomes Res 2010, 10(5):567-582.
47. Drummond M., Sculpher M., Torrance G., et al. Methods for the economic evaluation of health care programmes 2005, Oxford University Press, Oxford (United Kingdom). 3rd edition.
48. Corvò R. Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiother Oncol 2007, 85(1):156-170.
49. Young R.J., Rischin D., Fisher R., et al. Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2011, 20(6):1230-1237.
50. Lang K., Sussman M., Friedman M., et al. Incidence and costs of treatment-related complications among patients with advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2009, 135(6):582-588.
51. Elting L.S., Cooksley C.D., Chambers M.S., et al. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys 2007, 68(4):1110-1120.
52. Peterman A., Cella D., Glandon G., et al. Mucositis in head and neck cancer: economic and quality-of-life outcomes. J Natl Cancer Inst Monographs 2001, 29:45-51.
53. Aviv J.E., Sataloff R.T., Cohen M., et al. Cost-effectiveness of two types of dysphagia care in head and neck cancer: a preliminary report. Ear Nose Throat J 2001, 80(8):553-556. 558.
54. Chambers M.S., Garden A.S., Kies M.S., et al. Radiation-induced xerostomia in patients with head and neck cancer: pathogenesis, impact on quality of life, and management. Head Neck 2004, 26(9):796-807.
55. Ragin C.C., Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer 2007, 121(8):1813-1820.
56. Vikram B. Changing patterns of failure in advanced head and neck cancer. Arch Otolaryngol 1984, 110(9):564-565.
57. Morris L.G., Sikora A.G., Patel S.G., et al. Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirus-associated oropharyngeal cancer. J Clin Oncol 2011, 29(6):739-746.
58. Kazi R., Manikanthan K., Pathak K.A., et al. Head and neck squamous cell cancers: need for an organised time-bound surveillance plan. Eur Arch Otorhinolaryngol 2010, 267(12):1969-1971.
59. Nonzee N.J., Dandade N.A., Patel U., et al. Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis: results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center. Cancer 2008, 113(6):1446-1452.
60. Mauskopf J.A., Sullivan S.D., Annemans L., et al. Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices-budget impact analysis. Value Health 2007, 10(5):336-347.
61. Borget I., Abramowitz L., Mathevet P. Economic burden of HPV-related cancers in France. Vaccine 2011, 29(32):5245-5249.
62. Remy V, Heitland W, Klussmann J, et al. Economic burden of HPV-related head & neck cancer and anal cancers in Germany. Presentation at ISPOR 14th Annual European Congress, Madrid (Spain). November 5-8, 2011.
63. Xie F., Thumboo J., Fong K.Y., et al. A study on indirect and intangible costs for patients with knee osteoarthritis in Singapore. Value Health 2008, 11(Suppl 1):S84-S90.
64. Leardini G., Salaffi F., Montanelli R., et al. A multicenter cost-of-illness study on rheumatoid arthritis in Italy. Clin Exp Rheumatol 2002, 20(4):505-515.
65. Fautrel B., Clarke A.E., Guillemin F., et al. Valuing a hypothetical cure for rheumatoid arthritis using the contingent valuation methodology: the patient perspective. J Rheumatol 2005, 32(3):443-453.
66. Cancer trends progress report - costs of cancer care [Internet]. Available at: Accessed December 7, 2011. http://progressreport.cancer.gov/doc_detail.asp%3Fpid=1%26did=2009%26chid=95%26coid=926%26mid.
67. CDC - number of HPV-associated cancer cases per year [Internet]. Available at: Accessed December 8, 2011. http://www.cdc.gov.ezproxy.welch.jhmi.edu/cancer/hpv/statistics/cases.htm.
68. Jemal A., Siegel R., Xu J., et al. Cancer statistics, 2010. CA Cancer J Clin 2010, 60(5):277-300.
69. Bradley C.J., Yabroff K.R., Dahman B., et al. Productivity costs of cancer mortality in the United States: 2000-2020. J Natl Cancer Inst 2008, 100(24):1763-1770.
70. Siegel J.E., Weinstein M.C., Russell L.B., et al. Recommendations for reporting cost-effectiveness analyses. Panel on cost-effectiveness in health and medicine. JAMA 1996, 276(16):1339-1341.
71. Garrison L.P., Mansley E.C., Abbott T.A., et al. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report-part II. Value Health 2010, 13(1):8-13.
72. Bridges J.F.P., Onukwugha E., Mullins C.D. Healthcare rationing by proxy: cost-effectiveness analysis and the misuse of the $50,000 threshold in the US. Pharmacoeconomics 2010, 28(3):175-184.
73. Chambers J.D., Neumann P.J., Buxton M.J. Does Medicare have an implicit cost-effectiveness threshold?. Med Decis Making 2010, 30(4):E14-E27.
74. Neumann P.J., Weinstein M.C. Legislating against use of cost-effectiveness information. N Engl J Med 2010, 363(16):1495-1497.
75. Nijdam W., Levendag P., Noever I., et al. Cancer in the oropharynx: cost calculation of different treatment modalities for controlled primaries, relapses and grade III/IV complications. Radiother Oncol 2005, 77(1):65-72.
76. Psyrri A., Cohen E. Oropharyngeal cancer: clinical implications of the HPV connection. Ann Oncol 2011, 22(5):997-999.
77. D'Souza G., Kreimer A.R., Viscidi R., et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007, 356(19):1944-1956.
78. Lowy D.R., Munger K. Prognostic implications of HPV in oropharyngeal cancer. N Engl J Med 2010, 363(1):82-84.
79. Dedhia R.C., Smith K.J., Johnson J.T., et al. The cost-effectiveness of community-based screening for oral cancer in high-risk males in the United States: a Markov decision analysis approach. Laryngoscope 2011, 121(5):952-960.
80. Lingen M.W. Brush-based cytology screening in the tonsils and cervix: there is a difference!. Cancer Prev Res (Phila) 2011, 4(9):1350-1352.
81. Fakhry C., Rosenthal B.T., Clark D.P., et al. Associations between oral HPV16 infection and cytopathology: evaluation of an oropharyngeal "pap-test equivalent" in high-risk populations. Cancer Prev Res (Phila) 2011, 4(9):1378-1384.
82. Kreimer A.R., Chaturvedi A.K. HPV-associated oropharyngeal cancers-are they preventable?. Cancer Prev Res (Phila) 2011, 4(9):1346-1349.
83. Beutels P., Jit M. A brief history of economic evaluation for human papillomavirus vaccination policy. Sex Health 2010, 7(3):352-358.
84. Kim J.J. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis 2010, 10(12):845-852.
85. de Kok I.M., Habbema J.D., van Rosmalen J., et al. Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness?. Eur J Cancer 2011, 47(3):428-435.
86. Dayyani F., Etzel C.J., Liu M., et al. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol 2010, 2:15.
87. Kim J.J. The role of cost-effectiveness in U.S. vaccination policy. N Engl J Med 2011, 365(19):1760-1761.
88. Kim J.J., Goldie S.J. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008, 359(8):821-832.
89. Finkelstein E.A., Fiebelkorn I.C., Wang G. National medical spending attributable to overweight and obesity: how much, and who's paying?. Health Aff (Millwood) 2003, (Suppl Web Exclusives). W3-219-W3-226.
90. Hogan P., Dall T., Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care 2003, 26(3):917-932.
91. Sullivan P.W., Ghushchyan V.H., Slejko J.F., et al. The burden of adult asthma in the United States: evidence from the Medical Expenditure Panel survey. J Allergy Clin Immunol 2011, 127(2):363-369. e1-3.
92. Blanciforti L.A. Economic burden of dermatitis in US workers. J Occup Environ Med 2010, 52(11):1045-1054. [corrected].
93. Ramsey S.D. How should we value lives lost to cancer?. J Natl Cancer Inst 2008, 100(24):1742-1743.